# Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

> **NCT01362439** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag S.p.A.** · enrollment: 133 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone ER

## Key facts

- **NCT ID:** NCT01362439
- **Lead sponsor:** Janssen-Cilag S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2010-03
- **Final completion:** 2010-03
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2013-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01362439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01362439, "Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01362439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*